IRIS Accounts Production v25.2.0.378 08950877 Board of Directors 1.4.24 31.3.25 31.3.25 20.8.2025 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh089508772024-03-31089508772025-03-31089508772024-04-012025-03-31089508772023-03-31089508772023-04-012024-03-31089508772024-03-3108950877ns15:EnglandWales2024-04-012025-03-3108950877ns14:PoundSterling2024-04-012025-03-3108950877ns10:Director12024-04-012025-03-3108950877ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3108950877ns10:SmallEntities2024-04-012025-03-3108950877ns10:Audited2024-04-012025-03-3108950877ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3108950877ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3108950877ns10:FullAccounts2024-04-012025-03-3108950877ns10:Director22024-04-012025-03-3108950877ns10:Director32024-04-012025-03-3108950877ns10:Director72024-04-012025-03-3108950877ns10:Director92024-04-012025-03-3108950877ns10:Director102024-04-012025-03-3108950877ns10:Director112024-04-012025-03-3108950877ns10:Director122024-04-012025-03-3108950877ns10:Director132024-04-012025-03-3108950877ns10:Director142024-04-012025-03-3108950877ns10:Director152024-04-012025-03-3108950877ns10:Director162024-04-012025-03-3108950877ns10:RegisteredOffice2024-04-012025-03-3108950877ns5:CurrentFinancialInstruments2025-03-3108950877ns5:CurrentFinancialInstruments2024-03-3108950877ns5:RetainedEarningsAccumulatedLosses2025-03-3108950877ns5:RetainedEarningsAccumulatedLosses2024-03-3108950877ns5:LandBuildingsns5:ShortLeaseholdAssets2024-04-012025-03-3108950877ns5:FurnitureFittings2024-04-012025-03-3108950877ns5:ComputerEquipment2024-04-012025-03-3108950877ns5:LandBuildingsns5:ShortLeaseholdAssets2024-03-3108950877ns5:FurnitureFittings2024-03-3108950877ns5:ComputerEquipment2024-03-3108950877ns5:LandBuildingsns5:ShortLeaseholdAssets2025-03-3108950877ns5:FurnitureFittings2025-03-3108950877ns5:ComputerEquipment2025-03-3108950877ns5:LandBuildingsns5:ShortLeaseholdAssets2024-03-3108950877ns5:FurnitureFittings2024-03-3108950877ns5:ComputerEquipment2024-03-3108950877ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3108950877ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-31
REGISTERED NUMBER: 08950877 (England and Wales)












HEALTH INNOVATION WESSEX LIMITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


HEALTH INNOVATION WESSEX LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2025







DIRECTORS: Ms F E Driscoll
N J Johnson
Ms A S Whitfield
Professor A D Pandyan
Dr D J Baylis
Dr J P Johnson
Professor A Richardson
Professor A J Chauhan
Ms N J Hamlet
Professor P R Worsley
Professor C J Barnes
Dr P M Wilson



REGISTERED OFFICE: Innovation Centre
Southampton Science Park
2 Venture Road
Chilworth
Hampshire
SO16 7NP



REGISTERED NUMBER: 08950877 (England and Wales)



SENIOR STATUTORY
AUDITOR:
Matt Cooper ACA



AUDITORS: Hopper Williams & Bell Limited
Statutory Auditor
Highland House
Mayflower Close
Chandler's Ford
Eastleigh
Hampshire
SO53 4AR

HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

BALANCE SHEET
31 MARCH 2025

2025 2024
as restated
Notes £ £
FIXED ASSETS
Tangible assets 4 40,786 48,917
Investments 5 - -
40,786 48,917

CURRENT ASSETS
Debtors 6 336,743 351,699
Investments 7 810,422 810,000
Cash at bank 3,547,702 3,192,513
4,694,867 4,354,212
CREDITORS
Amounts falling due within one year 8 (3,842,353 ) (3,535,211 )
NET CURRENT ASSETS 852,514 819,001
TOTAL ASSETS LESS CURRENT
LIABILITIES

893,300

867,918

RESERVES
Retained earnings 893,300 867,918
893,300 867,918

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 August 2025 and were signed on its behalf by:





Ms N J Hamlet - Director


HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


1. STATUTORY INFORMATION

Health Innovation Wessex Limited is a private company, limited by guarantee, registered in England and Wales. The company's registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standards applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies' regime.

The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value.

The principal accounting policies adopted are set out below.

Going Concern
The directors have concluded that with the right management actions the company is a going concern for at least 12 months following the signature of the financial statements. Accordingly the directors have prepared the financial statements on this basis.

Turnover
Turnover represents amounts invoiced excluding value added tax, adjusted for amounts deferred or accrued where appropriate. Income is recognised in the period in which it is due. Income received on a conditional basis, including core income from NHS England, is deferred to the following year to the extent that the conditions are not fully discharged and expenditure against that income has not been incurred by the year end.

Provision for impairment of income is made where there is objective evidence that the company will not be able to collect all amounts due.

Income generated from the provision of other services is recognised at the time such services are provided.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Short leasehold improvements - Over the length of the lease
Fixtures and fittings - Straight line over 5 years
Computer equipment - Straight line over 3 - 5 years


HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Financial assets
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets, which include trade and other receivables and cash and bank balances are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method, unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial liabilities
Basic financial liabilities, which include trade and other payables, are initially measured at transaction price and subsequently measured at amortised cost, unless the arrangement constitutes a financing transaction where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of the proceeds received net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Fixed asset investments
Other investments are recognised at cost less any provision for impairment.

Current asset investments
Current asset investments comprise fixed term bank deposits. These investments are classified as a basic financial instrument and are measured at amortised cost.

HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued

Leasing commitments
Leases where substantially all risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessors) are recognised in the Statement of Income and Retained Earnings on a straight line basis over the period of the lease.

Agency arrangements
The company has entered into a partnership agreement for Wessex Health Partnership which involves the use of the assets and other resources of the venturers. Health Innovation Wessex Limited does not have control over the application of the funds. The funds received and paid and any balances held are disclosed in the agency arrangements note below.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 62 (2024 - 48 ) .

4. TANGIBLE FIXED ASSETS
Short Fixtures
leasehold and Computer
improvements fittings equipment Totals
£ £ £ £
COST
At 1 April 2024 8,210 33,289 99,510 141,009
Additions - 235 13,825 14,060
Disposals - (291 ) - (291 )
At 31 March 2025 8,210 33,233 113,335 154,778
DEPRECIATION
At 1 April 2024 8,210 26,918 56,964 92,092
Charge for year - 1,628 20,272 21,900
At 31 March 2025 8,210 28,546 77,236 113,992
NET BOOK VALUE
At 31 March 2025 - 4,687 36,099 40,786
At 31 March 2024 - 6,371 42,546 48,917

5. FIXED ASSET INVESTMENTS

This relates to an investment with a cost of £100,877 which was fully impaired in the year ended 31 March 2023. A review of this investment has been completed during the year, and it is still considered to be fully impaired as at the balance sheet date.

HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
as restated
£ £
Trade debtors 272,940 169,509
Other debtors 63,803 182,190
336,743 351,699

7. CURRENT ASSET INVESTMENTS
2025 2024
as restated
£ £
Bank deposits 810,422 810,000

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
as restated
£ £
Trade creditors 565,313 492,066
Taxation and social security 123,179 -
Other creditors 3,153,861 3,043,145
3,842,353 3,535,211

9. LEASING AGREEMENTS

Total operating lease commitments as at 31 March 2025 were £17,933 (2024 - £63,796) in relation to office rental and equipment.

10. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Matt Cooper ACA (Senior Statutory Auditor)
for and on behalf of Hopper Williams & Bell Limited

11. AGENCY ARRANGEMENTS

Health Innovation Wessex Limited entered into a partnership agreement in the year ended 31 March 2024 for which it receives and distributes funds as an agent for Wessex Health Partnership. In the accounting period, Health Innovation Wessex Limited received £720,965 (2024: £1,475,000) and disbursed £699,289 (2024: £559,223) from the fund. An amount of £937,453 (2024:£915,777) is included in other creditors relating to undistributed funds.

Additionally other miscellaneous grant agreements were entered into which reflected an agency agreement. At 1 April 2024, a brought forwards balance of £272,774 was included within the accounts relating to these agreements. Income of £894,500 was received during the year and £188,475 was disbursed. An amount of £978,799 is included in other creditors at the balance sheet date relating to undistributed funds.

HEALTH INNOVATION WESSEX LIMITED (REGISTERED NUMBER: 08950877)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


12. LIMITED BY GUARANTEE

The company is limited by guarantee and does not have share capital. In the event of the company being wound up, the members have each agreed to contribute the sum of £1 towards the assets of the company.

13. PRIOR YEAR ADJUSTMENTS

The financial statements have been restated for the year ended 31 March 2024 to correct misallocated balance sheet nominals relating to the treatment of Wessex Health Partners agency arrangement.

The balance sheet has changed as follows:

Bank - Increase of £133,268
Trade debtors - Increase of £100,000
Trade creditors - Increase of £5,763
Other debtors - Increase of £6,507
Other creditors - Increase of £234,012

There are no adjustments which effect either the reserves of the company, the profit included in the statement of income and retained earnings, or corporation tax.